Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experime ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.

Donald Trump slammed Kamala Harris as a socialist on the campaign trail, writes Bruce Fein, but his nationalization of U.S.

A proposed new federal law could provide some competitive guardrails for the company's most important product.